Differential gene expression by RNA-seq during Alzheimer's disease-like progression in the Drosophila melanogaster model
Jéssica Regina da Costa Silva,Patrícia Tieme Fujimura,Letícia Leandro Batista,Serena Mares Malta,Romualdo Morandi Filho,Matheus Henrique Silva,Aline Gomes de Souza,Ana Paula Mendes Silva,Luiza Diniz Ferreira Borges,Victor Alexandre Félix Bastos,Jamile Fernanda Silva Cossolin,José Eduardo Serrão,Ana Maria Bonetti,Luiz Carlos Oliveira Júnior,Carlos Ueira-Vieira
DOI: https://doi.org/10.1016/j.neures.2022.02.003
Abstract:Alzheimer's disease (AD) is characterized by progressive, irreversible loss of memory and cognitive function. Drosophila melanogaster and other animal models are used to study several diseases, in order to elucidate unknown mechanisms and develop potential therapies. Molecular studies require biological samples and, for neuropathologies such as AD biopsy of the human brain, are invasive and potentially damaging. The solution is to use animal models, such as D. melanogaster, which is a model organism that can replace mammalian organisms in such studies. In this study, we evaluated the climbing ability and differential gene expression during AD progression due to the amylodoigenic pathway using RNA-seq, and we performed an in silico analysis of a fruit fly AD-like GFP (Green Fluorescent Protein) model with GFP expression in the pan-neural elav driver. A total of 1388 genes were differentially expressed in all analyzed groups. The main pathways related to those Differentially Expressed Genes (DEGs) during aging and AD progression were evaluated using the fly genes and human orthologs, in order to link genomic information to higher-order functional information with gene pathway mapping. We identified pathways present in all analyzed groups, such as metabolic pathways, ribosomal pathways, proteasome pathways and immune system pathways. Some of the genes were validated by qPCR. Knockdown of CG17754 gene by RNAi promoted degeneration in the fly eye, validating these findings in vivo. The identification of similarities in molecular pathways between the transgenic fly AD-like GFP model and mammals related to AD provides new insights into the use of this fly in screening novel anti-AD drugs.